India's anti-obesity drug market shows significant growth. It has increased fourfold in five years. Lifestyle diseases and ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity now is under attack on multiple fronts, from ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025.

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven ...

Trump previously floated a 25% tariff on all imported drugs, though they were unaffected by recent reciprocal levies.

IPL is passé, and Lok Sabha elections no longer carry the same thrill. A new battle is brewing in India, and is ready to take ...

WeightWatchers faces bankruptcy with £1.25 billion ($1.6 billion) in debt, losing clients to drugs like Ozempic. Can the ...

Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.